EYPT News and Press, EyePoint Pharmaceuticals Inc. From 12/05/23

2023-12-05 07:55:14 ET EyePoint Pharmaceuticals (NASDAQ: EYPT) stock price has surged hard this week as it became a favorite among StockTwits traders. The shares jumped to a high of $22.40 on Monday, its highest point since November 2019. They have now risen by over 778% from the lowest...

2023-12-04 16:26:58 ET More on EyePoint Pharmaceuticals Shorting EyePoint Pharmaceuticals Ahead Of Davio-2 Wet-AMD Data: Potential 78% Gain Countdown To Clarity: EyePoint's December Data Delivery EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call ...

2023-12-04 12:47:12 ET Gainers: Hawaiian Holdings ( HA ) +187% . EyePoint Pharmaceuticals ( EYPT ) +177% . SilverSun Technologies ( SSNT ) +176% . Alterity Therapeutics Ltd ( ATHE ) +122% . View ( VIEW ) +82% . enGene Holding...

2023-12-04 12:22:42 ET DENVER, Colo., Dec. 4, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual midday volume; SilverSun Technologies Inc (NASDAQ: SSNT), EyePoint Pharmaceuticals Inc (NASDAQ: EYPT), Alterity Therap...

2023-12-04 10:02:05 ET More on Health Care Select Sector SPDR Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble For further details see: Ocular Therapeutix, EyePoint Pharmaceuticals among healthcare movers

2023-12-04 10:01:55 ET DENVER, Colo., Dec. 4, 2023 ( www.247marketnews.com )- The following companies published announcements or are trading higher on higher-than-usual volume; EyePoint Pharmaceuticals Inc (NASDAQ: EYPT), SilverSun Technologies Inc (NASDAQ: SSNT), Alterity Therapeutics ...

2023-12-04 08:26:05 ET More on EyePoint Pharma Shorting EyePoint Pharmaceuticals Ahead Of Davio-2 Wet-AMD Data: Potential 78% Gain Countdown To Clarity: EyePoint's December Data Delivery EyePoint Pharmaceuticals, Inc. (EYPT) Q3 2023 Earnings Conference Call Transcrip...

– Both EYP-1901 cohorts demonstrated a statistically non-inferior change in BCVA versus aflibercept control with a numerical difference of only -0.3 and -0.4 letters, respectively for the 2 mg and 3 mg dose at blended six-month endpoint – – Positive safety p...

2023-11-30 16:39:16 ET Summary EyePoint Pharmaceuticals, Inc. is expected to release Phase 2 data for its product candidate EYP-1901 in treating wet-AMD in December. The Phase 2 data suggests that the study may fail, with a difference in BCVA between EYP-1901 and control Eylea of ...

2023-11-24 13:00:31 ET More on the markets Broad Turn In Weekly Momentum Bodes Well For Stocks SPY: When Indicators Speak, The Year-End Rally Makes Little Sense 2024 U.S. Equities Outlook: Expect Bulls To Win This Round, Too Best stocks for when the 10-year T...